Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients With Post-COVID-19 Syndrome (RIMOCOVID-1)

NCT07930637 is registered in ClinicalTrials.gov with Sinfatin S.L as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07930637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients With Post-COVID-19 Syndrome (RIMOCOVID-1)
Lead sponsor
Sinfatin S.L
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 6, 2026
Completion date
March 31, 2028
Enrollment
80 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

post-covid-19 syndrome

Arms

As registered; 2 arms.

  • Rimonabant 5 mg ExperimentalRimonabant

    Participants receive rimonabant 5 mg orally once daily for 90 days.

  • Placebo Placebo comparatorPlacebo

    Participants receive matching placebo orally once daily for 90 days.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Symbol Digit Modalities Test (SDMT) Baseline to end of follow-up (day 135)

    The SDMT assesses cognitive processing speed using the validated Spanish version of the test. Participants must match symbols to their corresponding numbers within 90 seconds. The raw score is the number of correct responses, ranging from 0 to 110; higher scores indicate better performance. Age- and education-adjusted scores are calculated using Spanish normative data.

Lead sponsor's other trials

Sinfatin S.L, most recent start first.

Similar trials

Same condition (Post-Acute COVID-19 Syndrome) and phase, most recent start first.